Stay updated with breaking news from Placebo Controlled Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Promising results from a phase 2 trial of ENV-101, a novel hedgehog inhibitor, showed improvement in lung function and reduction of fibrosis in patients with idiopathic pulmonary fibrosis, said Paul Frohna, MD, PhD, PharmD.
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 -- HUTCHMED Limited today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new...
Investegate announcements from HUTCHMED Data to be Presented at EHA2024 Congress
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary...
27.02.2024 - GOTHENBURG, SWEDEN / ACCESSWIRE / February 27, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 27, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for ...